The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. https://ihannadkvv029079.anchor-blog.com/19451099/glp-3-retatrutide-a-comparative-analysis